- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04469153
Interest of the Dosage of Ferritin / Glycosylated Ferritin in COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus responsible for the pandemic called coronavirus disease 2019 (COVID-19), which appeared in China in December 2019 and which has spread rapidly around the world. Even if in the vast majority of viral infection results in a mild illness, it can also progress to a severe form with sometimes fatal consequences.
Indeed, clinical worsening, between the 7th and 10th days of the onset of symptoms, has been widely described since the start of the pandemic. This manifests itself at the biological level by hyperinflammation (VS, CRP, ferritin), coagulopathy (elevation of D-dimers, sometimes disseminated intravascular coagulation) and cell lysis (CPK, LDH).
At the same time, it was observed high levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-18), suggestive of a cytokine storm, and the first studies on therapeutic management targeting these cytokines are currently underway in COVID-19.
Such a profile strongly recalls on the one hand the cytokine release syndrome (CRS, observed in CAR-T cell therapy in malignant hematology), and on the other hand the lymphohistiocytic activation syndrome (SALH). Systemic diseases, such as adult Still's disease and its pediatric side, can also be complicated by a cytokine storm, known as macrophagic activation syndrome (SAM, equivalent to secondary SALH). Under all these conditions, IL-1β, IL-18, IFN-γ and IL-6 seem to be key mediators of hyperinflammation.
Plasma ferritin is a biological marker of inflammation, long known, associated with various infectious, hematological and immunological conditions. An increase in ferritin levels has in particular been associated with an unfavorable development in certain infections such as influenza and certain authors have moreover shown an association between plasma ferritin and the evolution towards ARDS or death in patients. Its dosage is also used as a diagnostic tool for SAM, and could make it possible to differentiate the latter from severe sepsis in intensive care. Some authors have also noted it as a prognostic factor in Kawasaki disease or CRS.
The plasma dosage of ferritin, associated with that of its glycosylated fraction, could therefore be a diagnostic (difference between SAM and severe sepsis in intensive care), prognostic (evolution towards ARDS, mutation in intensive care, mortality) and therapeutic (indication of preemptive treatment with an inhibitor of IL-1 or IL6) in patients infected with SARS-CoV-2.
The objective of this study is to retrospectively assess the prognostic value of ferritin and glycosylated ferritin in SARS-CoV-2 infection in hospitalized.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Maxime FAUTER
- Phone Number: +33 4 26 73 26 36
- Email: maxime.fauter@chu-lyon.fr
Study Contact Backup
- Name: Yvan jamilloux
- Phone Number: +33 4 26 73 26 36
- Email: yvan.jamilloux@chu-lyon.fr
Study Locations
-
-
Rhone Alpes
-
Lyon 4, Rhone Alpes, France, 69317
- Recruiting
- Hopital de La Croix Rousse
-
Contact:
- Yvan Jamilloux
- Phone Number: +33 4 26 73 26 36
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient hospitalized in the internal medicine department of the Croix-Rousse hospital and positive for the SARS-COV 2 (nasopharyngeal sample, the test was appoved by the French national medical authorities).
Exclusion Criteria:
- Not applicable
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
SARS-COV 2 positive patient
57 SARS-COV-2 positive patients followed during the SARS-COV 2 epidemic in the internal medicine department of the Croix-Rousse hospital.
For each patient ferritin and glycosylated ferritin was analysed one time (biological analysis) at the entry of the hospitalization.
|
No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
assessment of the prognostic value of ferritin in sars-cov2 positiv patients
Time Frame: the time point is measured one time (biological analysis) at the beginning of the hospitalization ie: day 0 (retrospective analysis).
|
ferritin level will be assess by approved serological tests (French national medical authorities).
Ferritin analysis is considered abnormal when the level is > at 388 µg/L;
|
the time point is measured one time (biological analysis) at the beginning of the hospitalization ie: day 0 (retrospective analysis).
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020_FerriGly COVID
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on the Prognostic Value of Ferritin
-
Ruhr University of BochumUnknownIn the Study the Value of Capnography for Avoiding Complications During Sedation for PEG is Evaluated.Germany
-
Assiut UniversityNot yet recruitingthe Prognostic Value of Pre-treatment NLR in Patients With Locally Advenced Rectal Cancer and Post-treatment
-
Tokat Gaziosmanpasa UniversityUnknownMean Platelet Volume According to Serum Sodium Value | on Patients Who Will Have Transurethral Resection of the ProstateTurkey
-
Institute of Hematology & Blood Diseases HospitalNot yet recruitingThe Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
-
University of ZurichCompletedNon Anemic Patients With Iron Deficiency (Low Ferritin Value)Switzerland
-
Setint AI Robotic Sistem Egitim ve Danısmanlık...RecruitingPredictive Value of Tests | Vital Signs | Reference Values | Laboratory Critical Values | Relative Value ScalesTurkey
-
Erebouni Medical CenterFisher and Paykel HealthcareRecruitingPredictive Value of TestsArmenia
-
Medical University of SilesiaCompletedPredictive Value of Tests | IntubationPoland
-
National and Kapodistrian University of AthensCompletedAnatomic Features of the Neck and Preoperative Tests as Predictive Markers of Difficult LaryngoscopyAirway Management | Predictive Value of Tests
-
Medical University of SilesiaCompletedPredictive Value of Tests | Intubation;DifficultPoland